SeekingAlpha · Sep 19, 2026
Our Top 10 High Growth Dividend Stocks - September 2026
Learn how to pick high-growth dividend stocks using sustainability, quality scores, momentum, and sector diversity. Read this month's top 10 picks here.
NYSE · LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
$1,152.93
Down-$0.22 (-0.02%)
Updated Sep 20, 2026, 7:56 AM
SID Score
6.1/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 906.5B
- P/E ratio
- 49.16
- Dividend yield
- 0.67%
- 52-week range
- $850.51 – $1,292.65
- Volume
- 4.55M
- Avg. volume
- 3.8M
Price performance
LLY price history
1M range · 19 trading sessions · Daily adjusted prices
LLY closed at $1,152.93 after 19 trading sessions, down 7.54% for the selected period.
- Last close
- $1,152.93
- Period change
- -7.54%
- Period low
- $1,115.70
- Period high
- $1,246.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $1,150.00 | $1,157.60 | $1,140.27 | $1,152.93 | 4.55M |
| Sep 17, 2026 | $1,150.27 | $1,159.75 | $1,138.26 | $1,152.44 | 1.9M |
| Sep 16, 2026 | $1,137.31 | $1,151.23 | $1,132.63 | $1,137.82 | 1.48M |
| Sep 15, 2026 | $1,156.63 | $1,161.00 | $1,131.59 | $1,136.11 | 1.89M |
| Sep 14, 2026 | $1,142.20 | $1,153.95 | $1,130.5001 | $1,138.28 | 2.13M |
| Sep 11, 2026 | $1,129.405 | $1,131.44 | $1,113.2919 | $1,115.70 | 1.84M |
| Sep 10, 2026 | $1,126.08 | $1,133.79 | $1,120.52 | $1,123.00 | 2M |
| Sep 9, 2026 | $1,127.61 | $1,138.79 | $1,119.00 | $1,124.21 | 2.05M |
| Sep 8, 2026 | $1,133.00 | $1,134.53 | $1,113.55 | $1,123.91 | 2.4M |
| Sep 4, 2026 | $1,150.61 | $1,158.44 | $1,138.306 | $1,149.36 | 2.22M |
| Sep 3, 2026 | $1,170.00 | $1,171.66 | $1,137.50 | $1,159.60 | 2.55M |
| Sep 2, 2026 | $1,164.15 | $1,187.83 | $1,158.00 | $1,160.08 | 2.45M |
| Sep 1, 2026 | $1,188.00 | $1,188.325 | $1,156.8501 | $1,160.00 | 2.52M |
| Aug 31, 2026 | $1,168.47 | $1,171.4479 | $1,147.00 | $1,156.73 | 3.06M |
| Aug 28, 2026 | $1,172.66 | $1,180.00 | $1,162.93 | $1,174.61 | 2.45M |
| Aug 27, 2026 | $1,182.25 | $1,190.11 | $1,171.71 | $1,176.10 | 2.74M |
| Aug 26, 2026 | $1,234.00 | $1,235.775 | $1,180.01 | $1,189.41 | 3.01M |
| Aug 25, 2026 | $1,249.00 | $1,264.73 | $1,229.79 | $1,233.66 | 2.14M |
| Aug 24, 2026 | $1,262.14 | $1,262.14 | $1,230.95 | $1,246.93 | 1.67M |
Latest LLY news
The latest Smart Investors Daily articles mentioning LLY.
Stock researchCompany · Overview
LLY research
Overview
Company profile and research snapshot.
Company profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $1,055.92
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Guggenheim | Buy | — |
| Sep 10, 2026 | HSBC | Reduce | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 19, 2026
A drugmaker is gaining from the side effects of weight-loss drugs
The consumer health company’s GLP-1 shelf strategy at CVS is paying off, and bigger retailers could follow.
Yahoo · Sep 18, 2026
Why Twist Bioscience Stock Skyrocketed This Week
It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.
Yahoo · Sep 18, 2026
What About the Energy Sector?
Readers weigh in on energy investments, retirees’ dilemma, a Social Security fix, lessons from 9/11, and the case for natural-gas company Equinor.
AI research layers
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company Stock Performance
Eli Lilly and Company shares closed at $1,152.22, reflecting a single-session decline of 1.66% per SID market data. Over the trailing one-month period, LLY has retreated 5.98%, though the stock maintains a positive three-month return of 3.64% and a 12.16% gain over the past year. The stock currently trades below its 50-day moving average of $1,178.64, suggesting near-term softness, while remaining well above its 200-day moving average of $1,061.15, which indicates the longer-term uptrend remains intact. The 14-day relative strength index sits at 39.1, approaching oversold territory below the conventional 30 threshold. According to Massive/Polygon data, average daily trading volume stands at approximately 3.80 million shares. LLY carries a beta of 0.369, indicating substantially lower volatility than the broader market, consistent with its defensive healthcare sector positioning. The company's market capitalization stands at approximately $906.5 billion.
Eli Lilly and Company Valuation Analysis
Eli Lilly trades at a price-to-earnings ratio of 49.16, a significant premium relative to the broader healthcare sector, reflecting the market's pricing of the company's high-growth GLP-1 franchise per SID market data. The PEG ratio stands at 1.47, suggesting the valuation is somewhat elevated even after adjusting for anticipated earnings growth, though it remains within a range that indicates growth expectations are not excessively stretched. The price-to-book ratio registers at 38.04, an exceptionally high multiple that underscores the market's emphasis on Eli Lilly's intangible assets, including its pharmaceutical pipeline and brand portfolio, rather than tangible book value. According to SEC filings, the company offers a dividend yield of approximately 0.59%, a modest payout reflecting management's prioritization of reinvestment into research and development. These valuation metrics collectively position LLY as a premium-priced growth name within the healthcare sector, commanding multiples that depend on sustained revenue acceleration.
Smart Money Activity for LLY
Eli Lilly's composite smart money score stands at 46 out of 100, registering a neutral signal according to SID market data. The institutional confidence component scores a perfect 25 out of 25, reflecting robust ownership and sustained positioning by major fund managers per 13F institutional filings. In contrast, the insider activity component scores just 4.1 out of 25, indicating limited conviction from company executives. According to SEC Form 4 filings, there have been 9 insider transactions over the past 90 days, comprising 5 purchases and 4 sales, suggesting a modestly balanced but relatively active insider trading period. The dark pool activity score registers at 9.2 out of 25, pointing to below-average institutional block trading activity. Congressional trading interest scores 7.6 out of 25, indicating moderate legislative attention. The divergence between maximal institutional confidence and weaker insider and dark pool signals creates a mixed overall picture, with large asset managers maintaining strong positions while other smart money indicators remain subdued.
Eli Lilly and Company Earnings Outlook
Eli Lilly has delivered a consistent pattern of earnings beats across its three most recent reporting periods, according to company earnings reports. In the most recent quarter reported on August 5, 2026, the company posted earnings per share of $8.38 against analyst estimates of $6.01, representing a substantial positive surprise of $2.37 or approximately 39.4%. The prior quarter, reported April 30, 2026, showed EPS of $8.55 versus the $6.85 consensus, a $1.70 beat. The February 4, 2026 quarter also exceeded expectations with $7.54 in EPS against estimates of $6.96. Looking ahead, the next earnings report is scheduled for August 6, 2026, with analyst estimates currently projecting EPS of $8.84. The trajectory of upward earnings surprises reflects strong commercial execution, particularly in the company's metabolic health portfolio. The magnitude of these beats has consistently exceeded 8%, indicating analysts may continue to underestimate the company's earnings power.
Wall Street Analyst Ratings for LLY
Wall Street consensus on Eli Lilly remains predominantly bullish, with the majority of recent analyst actions reaffirming positive ratings per SID consensus data. On September 18, 2026, Guggenheim maintained its Buy rating, while Truist Securities reiterated Buy on August 7, 2026. Both Wells Fargo and Cantor Fitzgerald maintained Overweight ratings on August 6, 2026, coinciding with the company's earnings release, according to Wall Street analyst reports. The sole dissenting voice comes from HSBC, which reiterated its Reduce rating on September 10, 2026, representing a contrarian bearish stance. Notably, none of the five most recent analyst actions involved rating changes, with each firm maintaining its prior position, suggesting established conviction levels on both sides. The four-to-one ratio of bullish-to-bearish ratings among recent coverage reflects broad confidence in Eli Lilly's growth trajectory, particularly surrounding its GLP-1 receptor agonist portfolio. The consensus view remains constructive despite the stock's premium valuation multiples.
